Published in Ann Surg on July 01, 2006
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev (2010) 3.24
Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol (2011) 1.98
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun (2009) 1.74
Chemokines in tumor progression and metastasis. Oncotarget (2013) 1.64
Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res (2009) 1.40
Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia (2007) 1.25
CXCR4 regulates the early extravasation of metastatic tumor cells in vivo. Neoplasia (2009) 1.21
The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res (2009) 1.18
miR-133b, a muscle-specific microRNA, is a novel prognostic marker that participates in the progression of human colorectal cancer via regulation of CXCR4 expression. Mol Cancer (2013) 1.15
The chemokine receptor CXCR4 strongly promotes neuroblastoma primary tumour and metastatic growth, but not invasion. PLoS One (2007) 1.09
Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. Mol Cancer (2011) 1.08
CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks. Oncogene (2015) 1.07
Down-regulation of CXCL12 mRNA expression by promoter hypermethylation and its association with metastatic progression in human breast carcinomas. J Cancer Res Clin Oncol (2008) 1.05
The intricate role of CXCR4 in cancer. Adv Cancer Res (2014) 1.04
Decoding melanoma metastasis. Cancers (Basel) (2010) 1.02
CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma. World J Gastroenterol (2011) 0.98
Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells. PLoS One (2012) 0.98
CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities. Neurosurgery (2008) 0.92
Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients. Cancer Microenviron (2008) 0.92
Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. Mol Cancer (2014) 0.91
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol (2015) 0.91
Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis (2007) 0.90
CXCR4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer. Clin Exp Metastasis (2011) 0.88
CXC receptor-4 mRNA silencing abrogates CXCL12-induced migration of colorectal cancer cells. J Transl Med (2011) 0.88
The fine balance of chemokines during disease: trafficking, inflammation, and homeostasis. Methods Mol Biol (2013) 0.87
Mechanisms regulating colorectal cancer cell metastasis into liver (Review). Oncol Lett (2011) 0.83
Prognostic molecular biomarkers for cutaneous malignant melanoma. J Surg Oncol (2011) 0.82
In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2. J Transl Med (2011) 0.81
Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine (2012) 0.81
An update on miRNAs as biological and clinical determinants in colorectal cancer: a bench-to-bedside approach. Future Oncol (2015) 0.79
Chemokine receptor CXCR4 expression and lung cancer prognosis: a meta-analysis. Int J Clin Exp Med (2015) 0.78
CXCR4 expression predicts early liver recurrence and poor survival after resection of pancreatic adenocarcinoma. Clin Transl Gastroenterol (2012) 0.78
The expression of chemokine receptors CXCR3 and CXCR4 in predicting postoperative tumour progression in stages I-II colon cancer: a retrospective study. BMJ Open (2014) 0.77
Apigenin suppresses migration and invasion of transformed cells through down-regulation of C-X-C chemokine receptor 4 expression. Toxicol Appl Pharmacol (2013) 0.77
Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. Cytokine (2016) 0.76
CXCR4-CXCL12-CXCR7, TLR2-TLR4, and PD-1/PD-L1 in colorectal cancer liver metastases from neoadjuvant-treated patients. Oncoimmunology (2016) 0.75
Melittin inhibits tumor angiogenesis modulated by endothelial progenitor cells associated with the SDF-1α/CXCR4 signaling pathway in a UMR-106 osteosarcoma xenograft mouse model. Mol Med Rep (2016) 0.75
A putative molecular network associated with colon cancer metastasis constructed from microarray data. World J Surg Oncol (2017) 0.75
MSH2 and CXCR4 involvement in malignant VIPoma. World J Surg Oncol (2012) 0.75
Prognostic Value of High CXCR4 Expression in Renal Cell Carcinoma: A System Review and Meta-Analysis. Dis Markers (2015) 0.75
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64
The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15
Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med (1998) 12.80
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med (2004) 11.71
The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (1996) 11.21
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 9.25
A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res (1987) 7.43
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg (2004) 6.75
Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature (2003) 5.57
Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A (2003) 3.72
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol (2004) 3.50
Chemokine receptors and their role in inflammation and infectious diseases. Blood (2000) 3.40
The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res (2003) 3.03
The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem (1998) 2.88
Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res (2000) 2.61
Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol (2005) 2.41
Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res (2005) 2.28
The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol (2002) 2.27
CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood (2002) 2.10
Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood (2004) 2.05
Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res (2003) 1.99
Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene (2003) 1.96
SDF-1 alpha induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells. Development (2001) 1.94
Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol (2004) 1.81
Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer (2004) 1.78
Results of hepatic resection for sarcoma metastatic to liver. Ann Surg (2001) 1.75
CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther (2004) 1.74
c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res (2003) 1.73
Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol (2001) 1.57
Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem (2001) 1.52
CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res (2004) 1.50
Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin Exp Metastasis (1992) 1.40
Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res (1997) 1.35
Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin (2001) 1.32
Identification of allosteric peptide agonists of CXCR4. J Biol Chem (2002) 1.19
Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg (2001) 1.14
Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent. FEBS Lett (2004) 1.12
Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int J Cancer (2005) 1.10
A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun (2004) 1.01
Why tumors travel to certain sites still puzzles researchers. J Natl Cancer Inst (1998) 0.77
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
A landscape of driver mutations in melanoma. Cell (2012) 12.61
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol (2005) 8.56
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2014) 4.61
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
Hospital costs associated with surgical complications: a report from the private-sector National Surgical Quality Improvement Program. J Am Coll Surg (2004) 3.65
Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol (2009) 3.36
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24
The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol (2010) 3.02
Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.96
More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg (2006) 2.78
Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol (2008) 2.53
Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol (2005) 2.41
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg (2007) 2.28
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res (2004) 2.05
Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem (2010) 2.03
Interpretive Diagnostic Error Reduction in Surgical Pathology and Cytology: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center and the Association of Directors of Anatomic and Surgical Pathology. Arch Pathol Lab Med (2015) 2.01
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol (2007) 1.97
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 1.81
Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer (2004) 1.78
Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol (2003) 1.78
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res (2009) 1.77
FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res (2010) 1.73
Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol (2006) 1.73
c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res (2003) 1.73
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res (2006) 1.72
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
The survival impact of the choice of surgical procedure after ipsilateral breast cancer recurrence. Am J Surg (2008) 1.71
Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res (2005) 1.70
Initial characterization of a dedicated breast PET/CT scanner during human imaging. J Nucl Med (2009) 1.68
Prognostic value of lymph node yield and metastatic lymph node ratio in medullary thyroid carcinoma. Ann Surg Oncol (2008) 1.66
LINE-1 hypomethylation during primary colon cancer progression. PLoS One (2011) 1.66
Prognostic implications of thick (>or=4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol (2002) 1.65
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 1.64
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron (2009) 1.60
Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem (2006) 1.58
Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics (2011) 1.55
Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg (2013) 1.52
Contemporary surgical treatment of advanced-stage melanoma. Arch Surg (2004) 1.52
Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol (2004) 1.50
CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res (2004) 1.50
An interaction of race and ethnicity with socioeconomic status in rectal cancer outcomes. Ann Surg (2011) 1.49
Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res (2003) 1.48
Influence of physician specialty on treatment recommendations in the multidisciplinary management of soft tissue sarcoma of the extremities. JAMA Surg (2013) 1.47
Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol (2003) 1.46
Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann Surg Oncol (2004) 1.44
Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J (2002) 1.43
Endoscopy education in general surgery residencies: meeting the new RRC requirements. J Surg Res (2010) 1.42
Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Oncol (2002) 1.42
Preoperative imaging of pulmonary metastases in patients with melanoma: implications for minimally invasive techniques. Arch Surg (2012) 1.41
Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol (2005) 1.40
Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol (2008) 1.39
Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lymphadenectomy. Ann Surg Oncol (2002) 1.39
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol (2002) 1.38